| Primary |
| Product Used For Unknown Indication |
41.9% |
| Drug Use For Unknown Indication |
13.8% |
| Helicobacter Infection |
8.0% |
| Pneumonia |
5.0% |
| Lower Respiratory Tract Infection |
4.9% |
| Bronchitis |
3.8% |
| Hypertension |
2.9% |
| Nasopharyngitis |
2.3% |
| Atypical Mycobacterial Infection |
2.0% |
| Mycobacterium Avium Complex Infection |
1.8% |
| Respiratory Tract Infection |
1.7% |
| Sinusitis |
1.6% |
| Cough |
1.5% |
| Pyrexia |
1.4% |
| Upper Respiratory Tract Inflammation |
1.4% |
| Prophylaxis |
1.3% |
| Pain |
1.2% |
| Infection |
1.2% |
| Asthma |
1.1% |
| Pharyngitis |
1.1% |
|
| Vomiting |
11.8% |
| Drug Interaction |
9.9% |
| Rhabdomyolysis |
7.1% |
| Rash |
6.0% |
| Renal Failure Acute |
5.9% |
| Urticaria |
5.1% |
| Pyrexia |
4.9% |
| Abortion Spontaneous |
4.4% |
| Tubulointerstitial Nephritis |
4.2% |
| Liver Disorder |
4.1% |
| Erythema Multiforme |
4.0% |
| Nausea |
4.0% |
| Swollen Tongue |
3.9% |
| Myalgia |
3.8% |
| Delirium |
3.7% |
| Angioedema |
3.6% |
| Dyspnoea |
3.5% |
| Hypoglycaemia |
3.4% |
| Somnolence |
3.2% |
| Agranulocytosis |
3.1% |
|
| Secondary |
| Product Used For Unknown Indication |
22.6% |
| Drug Use For Unknown Indication |
11.8% |
| Helicobacter Infection |
10.1% |
| Hiv Infection |
8.0% |
| Pneumonia |
5.3% |
| Mycobacterium Avium Complex Infection |
4.0% |
| Prophylaxis |
3.5% |
| Lower Respiratory Tract Infection |
3.5% |
| Hypertension |
3.2% |
| Drug Abuse |
3.2% |
| Bronchitis |
3.1% |
| Pyrexia |
3.0% |
| Pseudomonas Infection |
3.0% |
| Asthma |
2.9% |
| Mycobacterium Abscessus Infection |
2.6% |
| Nasopharyngitis |
2.2% |
| Sinusitis |
2.1% |
| Respiratory Tract Infection |
2.1% |
| Cough |
2.0% |
| Helicobacter Gastritis |
2.0% |
|
| Vomiting |
17.2% |
| Rhabdomyolysis |
9.0% |
| Pyrexia |
6.7% |
| Renal Failure Acute |
6.1% |
| White Blood Cell Count Increased |
5.5% |
| Tachycardia |
5.1% |
| Rash |
4.6% |
| Stevens-johnson Syndrome |
4.5% |
| Hypoglycaemia |
4.1% |
| Weight Decreased |
4.1% |
| Thrombocytopenia |
3.8% |
| Tubulointerstitial Nephritis |
3.8% |
| Toxic Epidermal Necrolysis |
3.5% |
| Drug Ineffective |
3.3% |
| Interstitial Lung Disease |
3.3% |
| Drug Eruption |
3.2% |
| Pneumonia |
3.2% |
| Suicidal Ideation |
3.2% |
| Diarrhoea |
3.0% |
| Pseudomembranous Colitis |
3.0% |
|
| Concomitant |
| Product Used For Unknown Indication |
26.8% |
| Drug Use For Unknown Indication |
12.8% |
| Hiv Infection |
9.8% |
| Prophylaxis |
9.1% |
| Rheumatoid Arthritis |
7.4% |
| Hypertension |
4.9% |
| Asthma |
3.4% |
| Bronchitis |
2.8% |
| Pneumonia |
2.5% |
| Infection Prophylaxis |
2.3% |
| Multiple Myeloma |
2.2% |
| Chronic Obstructive Pulmonary Disease |
2.2% |
| Mycobacterium Avium Complex Infection |
2.1% |
| Pain |
2.0% |
| Depression |
1.9% |
| Constipation |
1.7% |
| Pyrexia |
1.6% |
| Cough |
1.6% |
| Atypical Mycobacterial Infection |
1.5% |
| Osteoporosis |
1.5% |
|
| Pneumonia |
9.9% |
| Pyrexia |
9.3% |
| Vomiting |
9.3% |
| Rhabdomyolysis |
8.1% |
| White Blood Cell Count Decreased |
6.4% |
| Weight Decreased |
5.8% |
| White Blood Cell Count Increased |
5.8% |
| Interstitial Lung Disease |
5.4% |
| Pulmonary Embolism |
4.3% |
| Thrombocytopenia |
4.2% |
| Respiratory Failure |
3.8% |
| Sepsis |
3.6% |
| Rash |
3.4% |
| Liver Disorder |
3.3% |
| Renal Failure Acute |
3.3% |
| Platelet Count Decreased |
3.0% |
| Renal Failure |
3.0% |
| Renal Impairment |
2.8% |
| Tremor |
2.7% |
| Dyspnoea |
2.6% |
|
| Interacting |
| Product Used For Unknown Indication |
28.5% |
| Helicobacter Infection |
7.8% |
| Crohn's Disease |
7.6% |
| Pain |
7.2% |
| Lower Respiratory Tract Infection |
5.8% |
| Hypertension |
5.7% |
| Drug Use For Unknown Indication |
5.1% |
| Pneumonia |
4.6% |
| Gastritis |
2.8% |
| Anxiety |
2.7% |
| Mycobacterium Avium Complex Infection |
2.7% |
| Respiratory Tract Infection |
2.7% |
| Schizophrenia |
2.6% |
| Gout |
2.1% |
| Type 2 Diabetes Mellitus |
2.1% |
| Upper Respiratory Tract Inflammation |
2.1% |
| Bronchitis |
1.9% |
| Renal Transplant |
1.9% |
| Urinary Tract Infection |
1.9% |
| Atypical Mycobacterial Infection |
1.8% |
|
| Drug Interaction |
30.4% |
| Hypoglycaemia |
5.7% |
| Renal Failure Acute |
5.1% |
| Sepsis |
5.1% |
| Vomiting |
5.1% |
| White Blood Cell Count Increased |
5.1% |
| International Normalised Ratio Increased |
4.4% |
| Rhabdomyolysis |
4.4% |
| Toxicity To Various Agents |
3.8% |
| Inhibitory Drug Interaction |
3.2% |
| Pneumonia |
3.2% |
| Respiratory Depression |
3.2% |
| Ventricular Tachycardia |
3.2% |
| Vertigo |
3.2% |
| Drug Level Increased |
2.5% |
| Muscular Weakness |
2.5% |
| Myositis |
2.5% |
| Pancytopenia |
2.5% |
| Pneumonia Aspiration |
2.5% |
| Ventricular Dysfunction |
2.5% |
|
